Evident announced an alliance with Corista, Sakura Finetek USA and Visiopharm to deliver an automated, end-to-end workflow solution for pathology in the USA.
Evident, a wholly owned subsidiary of Olympus Corporation, announced the latest results from its ongoing joint research program to create an AI-based pathology diagnostic tool at the 20th annual meeting of the Japanese Society of Digital Pathology.